ADIL: Adial Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ADIL: Adial Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6.53
Enterprise Value ($M) 1.33
Book Value ($M) 5.88
Book Value / Share 0.92
Price / Book 1.11
NCAV ($M) 4.79
NCAV / Share 0.75
Price / NCAV 1.36

Profitability (mra)
Return on Invested Capital (ROIC) -2.22
Return on Assets (ROA) -4.55
Return on Equity (ROE) -5.58

Liquidity (mrq)
Quick Ratio 6.78
Current Ratio 6.78

Balance Sheet (mrq) ($M)
Current Assets 5.62
Assets 6.71
Liabilities 0.83
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 4.99 101.42

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 27,810 132,548 20.98
2024-11-21 5,304 42,834 12.38
2024-11-20 10,365 89,138 11.63
2024-11-19 22,322 144,959 15.40
2024-11-18 43,769 203,053 21.56

(click for more detail)

Similar Companies
ACB – Aurora Cannabis Inc. ACHV – Achieve Life Sciences, Inc.
ACXP – Acurx Pharmaceuticals, Inc. ADTX – Aditxt, Inc.
ADVM – Adverum Biotechnologies, Inc.


Financial data and stock pages provided by
Fintel.io